Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
A nurse administers an Ebola vaccine in Monrovia, Liberia, as part of a 2015 clinical research study. Photo: John Moore/Getty Images
An Ebola vaccine made by Merck has protected a group of volunteers for two years — the longest it has been shown to protect against the disease, according to a study published in Lancet Infectious Diseases.
The context: "A fast-acting, long-lasting vaccine given in a single dose would be an effective tool for controlling dangerous Ebola outbreaks," STAT's Helen Branswell reports.
Yes, but: The vaccine targets only one strain of Ebola, known as Zaire, and samples from additional trials will be needed to support these findings.
What's next: Merck is looking to apply for FDA approval of the candidate vaccine this year.
Stay tuned for: The lead author of the paper and an infectious disease specialist, Angela Huttner and her team have collected blood samples from volunteers in Geneva, Switzerland to see how the vaccine performs after three years, but they haven't analyzed them yet.
- Huttner told STAT: “Our hypothesis is that the values we’re seeing at two years shouldn’t change too much at three, four, and five years.”
Take note: Some experts in the industry believe a two-dose vaccine, like the ones being developed by Janssen Vaccines and Prevention BV, a subsidiary of Johnson & Johnson, may be better equipped at offering long-term protection.